Every 10-Q that The Oncology Institute Inc (TOI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TOI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOI filings page.
Starling Oncology, Inc. reported higher revenue and narrower losses for the three and six months ended June 30, 2026. Total operating revenue reached $161,282 thousand in Q2 and $308,723 thousand year‑to‑date, driven by growth in specialty pharmacy and capitated patient services.
Loss from operations improved to $4,616 thousand in Q2 and $11,129 thousand year‑to‑date, with net loss of $9,789 thousand for the quarter and $12,281 thousand for six months. Operating cash flow turned positive at $9,725 thousand, and cash and equivalents increased to $41,094 thousand. The company remained in a stockholders’ deficit of $24,914 thousand and carried $79,867 thousand of senior secured convertible debt at June 30, 2026, which it repaid in full (approximately $86 million principal) on July 1, 2026.
The Oncology Institute, Inc. reported total revenue of $147.4 million for the three months ended March 31, 2026, up from $104.4 million a year earlier, driven mainly by growth in specialty pharmacy and patient services.
The company posted a net loss of $2.5 million, a significant improvement from a $19.6 million loss in the prior-year quarter, with net loss per share narrowing to $0.02 from $0.21. Operating cash outflow was $2.2 million, and cash and cash equivalents were $30.3 million as of March 31, 2026. Long-term debt, primarily a senior secured convertible note, stood at $78.6 million net, while stockholders’ deficit was $16.3 million.
Management evaluated liquidity and, despite the accumulated deficit of $273.9 million, concluded the company has sufficient resources to fund operations for at least one year from issuance of these financial statements.
The Oncology Institute, Inc. (TOI) reported Q3 2025 results with total operating revenue of $136.6 million, up from $99.9 million a year ago, driven mainly by dispensary sales. Dispensary revenue reached $75.9 million versus $48.2 million, while patient services were $60.2 million versus $49.8 million. Capitated revenue was $20.6 million versus $14.8 million.
The company posted a Q3 loss from operations of $8.1 million, improving from a $13.9 million loss, and a net loss of $16.5 million. Year‑to‑date revenue was $360.8 million with a net loss of $53.1 million. Cash and cash equivalents were $27.7 million at quarter‑end, and net cash used in operations was $27.8 million for the nine months.
TOI reduced SG&A and executed financing actions: a $20.0 million partial prepayment of its Senior Secured Convertible Notes and removal of the $40.0 million minimum cash covenant; approximately $16.5 million in gross proceeds from a private placement; and $11.8 million in aggregate gross proceeds under its at‑the‑market program, including 3.4 million shares sold in Q3. Long‑term debt was $76.2 million, and stockholders’ equity was a deficit of $12.3 million. Management concluded it has sufficient liquidity for at least one year.